Broad Market

· daily

Global High-Priority Regulatory Events — March 15, 2026

Across these two high-priority market event filings, themes center on operational stability amid rumors in the metals sector and upcoming earnings catalysts in IT services, both from major Indian firms with US exposure via ADRs. Hindalco's positive rumor verification highlights minimal disruption (<0.1% impact) from gas supplier force majeure, underscoring resilience in commodities amid geopolitical noise like Iran war reports. Infosys announces a high-materiality (9/10) board meeting for Q4/FY2026 results and potential dividend, signaling routine but critical capital allocation decisions under SEBI compliance. No direct period-over-period financial trends are reported in these event-driven filings, but forward-looking catalysts dominate, with Infosys' trading window closure (March 16-April 27, 2026) implying material non-public info. Portfolio-level patterns show low-risk clarification for Hindalco (materiality 3/10) versus high-impact earnings for Infosys, suggesting relative outperformance potential in IT over metals short-term. Market implications include reduced uncertainty for Hindalco and pre-earnings positioning for Infosys, with both reinforcing SEBI regulatory transparency.

2 high priority 2 total filings
· daily

Global High-Priority Regulatory Events — March 14, 2026

The 17 filings reveal a surge in high-priority distress events among Indian listed companies, dominated by insolvency proceedings (10/17), with 70% showing positive progress via settlements, unanimous approvals, and scheme sanctions, signaling potential turnarounds amid CIRP protections. Negative outliers include Reliance Communications' subsidiary fraud classification on ₹375 Cr pre-CIRP loans (₹125 Cr SBI), Tijaria Polypipes' new Bank of India insolvency petition, and Olympic Cards' ₹0.15 Cr loan default on ₹15.5 Cr facility. No aggregate period-over-period financial trends available, but specific metrics highlight distress like Olympic's ₹9.28 Cr bank borrowings and 100% creditor approvals in restructurings (e.g., Share India 99.8% equity votes). Open offers (Lykis, Satani Bearings) and minor regulatory actions (Manappuram ₹2.7L penalty) add neutral-to-positive M&A/takeover themes. Three medium-risk encumbrances (Anand Rathi Wealth, India Finsec, unknown) warrant monitoring. Portfolio implications: Bullish resolution momentum for alpha in distressed assets, bearish fraud/default risks for avoidance; key catalysts cluster March-April 2026.

17 high priority 17 total filings
· daily

US Material Events SEC 8-K Filings — March 13, 2026

The 50 8-K filings from March 13, 2026, reveal a surge in financing activities (12+ cases), including credit expansions, note issuances, and debt-for-equity swaps, signaling robust liquidity amid stable economic conditions; energy firms dominate positive developments with accretive acquisitions and $20.7B+ project financings. Executive transitions affect 15+ companies (resignations/appointments), mostly neutral/mixed but clustered in tech/healthcare, potentially signaling churn without major disagreements. Capital allocation trends favor shareholders via $10M repurchases (HealthStream), buyback permissions ($50M AMC), and hedging (Vitesse 67% 2026 oil hedged at $64-67/Bbl), contrasting dilutive raises (Olenox Series C, Functional Brands exchanges). M&A/asset sales (7 cases) show mixed pro forma impacts, e.g., Kaanapali $10.3M gain but sales declines YoY. No widespread margin compression; instead, operational enhancements (Battalion 30 drilling locations added) and forward contracts (ETHZilla 12-13% yields). Highest materiality events (10/10: IF Bancorp merger delist, Venture Global FID) imply sector rotation to energy/LNG; watch fintech tokenization and REIT dispositions for alpha.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 13, 2026

Across 50 SEC filings for March 13, 2026, key themes include mixed FY2025 results with revenue growth averaging +15% YoY in reporting companies (e.g., ONE Group +19.7%, Emerald +16.2%, Tonix +30% product rev) offset by Q4 weakness and margin pressures in hospitality/REITs, alongside robust capital allocation via dividends (GIII $0.10/share, Emerald $0.015/share, First Northern 5% stock dividend) and buybacks (Emerald $17.5M repurchased, $25M remaining; News Corp $1B program). Energy sector shines with Venture Global's $20.7B CP2 LNG financing (no equity dilution) positioning it as top US exporter at 100+ MTPA, and Battalion Oil's accretive acquisition adding 30 drilling locations. Pharma/biotech shows launches (Tonix TONMYA) but high cash burn; banks/REITs mixed with NIM expansion (First Northern +17 bps to 3.77%) but deposit declines. Forward guidance optimistic in hospitality/events (ONE Group $840-855M rev 2026, Emerald $490-495M), while insider activity neutral (Walmart 10b5-1 plans for diversification). Portfolio-level: 6/10 detailed filers issued upbeat 2026 guidance, but 4/10 reported net losses widening YoY; M&A/acquisitions in 5 filings signal consolidation. Implications: Favor energy/infrastructure over cyclical hospitality amid quiet deposit growth in banks.

32 high priority 18 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 13, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus with global insolvency/takeover/regulatory themes), key themes include robust energy project financings and acquisitions contrasting with Indian insolvencies and mixed bank/REIT 10-K results; period-over-period trends show 7/15 10-Ks with revenue growth averaging +20% YoY (e.g., Perfect Corp +14.9%, SenesTech +20%) but 4 with declines averaging -11% (Quest -13.2%), NIM expansions in 3 banks (+14-37 bps), and portfolio expansions in BDCs/lenders. Critical developments feature Venture Global's $8.6B CP2 LNG FID (total $20.7B financing, +100 MTPA capacity), BlackRock's stake increase in Sammaan Capital (+0.06%), and multiple Indian insolvencies (Punj Lloyd, Shree Hanuman). Capital allocation highlights buybacks (CCEP €1B completed, First Northern repurchase program), dividends (5% stock dividend), and financings; insider patterns show institutional buying but key resignations (Greenpanel President, Nine Energy GC). Market implications point to energy export strength amid LNG demand, bank resilience despite deposit shifts, and distress opportunities in India, with catalysts like CoC meetings and IPOs driving near-term volatility.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 13, 2026

Overnight SEC filings for March 13, 2026, reveal a mix of FY2025 10-K annual reports dominating (e.g., banks, pharma, REITs, BDCs), with period-over-period trends showing resilient revenue growth in select pharma/biotech (avg +25% YoY for Tonix, SenesTech, Vaxart) and banks (Red River net income +25% YoY, First Northern NII +4.8%), but widespread margin pressures and operating losses in industrials/REITs (Quest revenue -13% YoY, BRT NOI flat). Capital allocation leans positive with buybacks (News Corp $1B program, First Northern 1M+ shares authorized), dividends (BRT AFFO +3%), and financings (Karman +$100M revolver, Olenox $810k preferred). Auditor changes (Amplify material weakness) and litigation (Scilex fraud suit) flag risks, while M&A/acquisitions (Battalion 7k acres all-stock) and guidance (Emerald FY26 revenue $490-495M) offer catalysts. Sector themes include banking NIM expansion (Red River +14 bps to 3.38%) vs deposit declines, BDC portfolio ramps (Unknown Co net assets +huge from inception), and mixed pharma commercialization ramps amid high cash burn. Portfolio-level: 12/20 10-Ks mixed sentiment, cash positions strengthened in 8/15 reporting cos (e.g., Tonix to $207M), signaling near-term runway but watch for Q1 2026 guidance shifts. Actionable: Favor banks/BDCs with NIM/ROE gains, avoid litigation-exposed biotech.

35 high priority 15 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 12, 2026

Across 50 US SEC 8-K filings dated March 12, 2026, dominant themes include widespread board expansions and executive appointments (20+ instances, e.g., healthcare/tech sectors), signaling proactive governance refreshes amid growth ambitions. Capital raising activity is robust with 15+ financings/debt deals totaling >$3B (e.g., CACI $500M notes, NGL $950M term loan, Longeveron $30M PP), extending runways and refinancing maturities, though some mixed with dilution/waivers. M&A completions/ announcements (8 filings, e.g., Laird $38.5M Navitas, T Stamp dual acqs) highlight consolidation in consumer health/tech, while operational distress appears isolated (Vestand closures/resignations). No aggregate YoY/QoQ financial trends due to 8-K focus on events, but capital allocation leans toward debt optimization (10+ refinancings) over dividends/buybacks. Bullish sentiment prevails (60% positive/neutral), with healthcare (Longeveron trial data 3Q26) and fintech leading; bearish outliers in retail/food (Vestand). Implications: Favor liquidity-strong firms pre-earnings; monitor SPACs/mergers for catalysts. Portfolio pattern: Activist settlements (Turtle Beach) and CEO transitions (Build-A-Bear) indicate stabilizing managements.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 12, 2026

Across 50 SEC filings for March 12, 2026, FY2025 results reveal mixed performance with 12/20 10-Ks showing revenue growth averaging +15% YoY (e.g., CZFS NII +13.3%, Velocity loans +28%) but offset by impairments, losses, and margin pressures in 8 cases (avg net loss widening 50%). Capital allocation trends positive in 7 companies with buybacks/dividends totaling >$10B authorized (KLA $7B new, Ibotta +$100M). Healthcare/biotech outliers bullish on trials/acquisitions (Solid Biosciences robust data, Gyre $300M Cullgen deal), while consumer/retail mixed (Build-A-Bear +6.7% rev but guidance decline, Vivid Seats -31% GOV). Proxy season ramps up with 8 April 2026 meetings, neutral sentiment. Energy/financials show NIM expansions (CZFS +37bps, Velocity +26bps YoY) amid pledges/ATM raises signaling caution. Forward guidance cautious with 6 cuts (Gyre rev -4.8-13.8%, Vivid Seats Q1 $570-620M post -42% Q4), but capex disciplined ($155-185M ProFrac). Portfolio implication: Favor capital returners and biotech catalysts over cyclical decliners.

25 high priority 25 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 12, 2026

Across 50 filings dated March 12, 2026, focused on US SEC critical events, dominant themes include mixed financial results in biotech/pharma (persistent losses but some expense cuts), explosive AUM growth in crypto trusts offset by NAV declines from crypto price weakness (e.g., Grayscale trusts up 56-229% AUM YoY), and resilient loan/deposit growth in financials/banks (avg +13-25% YoY) amid NIM pressures. Aggregate period trends show revenue growth in 12/20 10-Ks averaging +15% YoY (outliers: Orrstown NII +28.7%, Sonida +23.9%; decliners: CompoSecure -86%, INTEST -12.9%), margin improvements in 7/15 (e.g., Healthpeak NOI +4%, Eastman gross +300bps), but net losses widening in 8/20 due to impairments/debt costs. Capital allocation leans shareholder-friendly with dividend hikes (HKHC +530% to $6.3M, Healthpeak 7% yield) and buybacks implied via cash builds, while M&A catalysts (Laird $38.5M acquisition, NCR Atleos merger consents) signal consolidation. Crypto ETF conversions and SPAC IPOs (Primeage $100M) highlight high-vol opportunities, but resignations (Vestand directors) and proxy equity plan oppositions (Enanta 22% against) flag governance risks. Portfolio implication: Overweight financials/REITs for stability, monitor crypto for ETF catalysts, avoid distressed biotech without pipeline wins.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 12, 2026

Overnight SEC filings reveal mixed FY2025 results across sectors, with financial institutions like Citizens Financial Services (NII +13.3% YoY, NIM to 3.50%) and Velocity Financial (loans +28% YoY, NI +53%) showing robust growth amid NIM expansion, while consumer-facing firms like Vivid Seats (GOV -31% YoY), Sleep Number (sales -16% YoY), and ProFrac (rev -11% YoY) reported sharp declines due to market softness and impairments. Capital allocation trends favor shareholders, with notable buybacks (Ibotta +$100M to $400M total, KLA new $7B program, AVY $572M), dividend hikes (KLA +21% to $2.30, Build-A-Bear +4.5% to $0.23), and debt refinancings (Southwest $500M term loan, Kodiak $1B notes). Biotech and SPACs offer catalysts (Solid Biosciences positive Phase 1/2 data, FDA Phase 3 alignment Q1 2026; Gyre $300M Cullgen acquisition Q2 2026), but energy explorers like New ERA (rev +66% offset by $12.1M impairment) and Serve Robotics (rev +46% but gross loss $15.4M) highlight volatility. Portfolio-level trends show 8/15 high-materiality 10-Ks with revenue growth averaging +15% YoY but margin compression in 6/15 (-avg 200bps), insider pledges in CZFS (multiple execs), and 12+ proxy votes clustered April 2026. Implications: Favor financials for stability, monitor consumer for tariff impacts, position for biotech/SPAC closings H1 2026.

25 high priority 25 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 11, 2026

Across 50 filings dated March 11, 2026, dominant themes include robust M&A activity (e.g., Cintas-Unifirst $5.5B, Sonida $1.8B, Sphere 3D-Cathedra all-stock merger), extensive debt/equity financings ($3.5B Consolidated Edison revolver, $9.5B Baker Hughes notes for Chart acquisition, $1B Global Payments notes), and high executive churn (17+ resignations/appointments across firms like ON Semiconductor, Biogen, Axon). Limited period-over-period data shows positive revenue trends (Cintas Q3 FY2026 +8.9% YoY to $2.84B, organic +8.2%; no widespread declines), but dilution risks from convertible notes (CERO $937.5k face, SunPower $10M debenture) and SPAC setbacks (Yotta merger termination). Capital allocation leans toward growth via acquisitions/synergies ($375M Cintas, 62% FFO accretion Sonida) over buybacks/dividends. Sector patterns highlight services/hospitality consolidation, bitcoin infrastructure M&A, and neutral-to-positive sentiment in 70% of filings. Implications: Bullish for acquirers like Cintas/Sonida on synergies/accretion; monitor dilution in small caps and SPAC extensions amid tight liquidity.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 11, 2026

Across 50 SEC filings from March 11, 2026, key themes include robust M&A and SPAC activity with approvals for TLGY/StablecoinX and Contango/Dolly Varden, contrasted by terminations like Yotta/DRIVEiT; mixed financial results with standout growth in Oracle (Q3 rev +22% YoY, Cloud +44%), TSS (FY rev +66% YoY), and Acacia (FY rev +133% YoY), but sharp declines in C3.ai (Q3 rev -46% YoY) and Target Hospitality (FY rev -17% YoY). Margin pressures persist in housing (Smith Douglas -440 bps FY gross margin) and logistics (Pangaea FY NI -33% despite Q4 rev +25%), while capital allocation favors buybacks (News Corp $1B program) and dividends (ICL 3.1% yield, JNJ +5% quarterly). SPAC ecosystem shows momentum with IPO filings (BEST SPAC II $100M, Pono $150M) and merger votes, but delisting risks (GameSquare) and dilutions loom. Cloud/AI sectors outperform with guidance raises (TSS 2026 EBITDA $20-22M, Serve Robotics rev $26M), signaling portfolio rotation opportunities amid sector dispersion. Overall, bullish signals in tech/logistics outweigh bearish earnings misses, with catalysts clustered in Q2 2026 AGMs and trials.

28 high priority 22 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 11, 2026

Across 50 filings in the 'Global High Priority Market Events' stream, dominant themes include intense SPAC activity (mergers, IPOs, terminations), major M&A completions/announcements (Cintas-UniFirst $5.5B, Sonida-CNHL $1.8B), mixed financial results with outliers like AeroVironment's 143% YoY revenue surge and C3.ai's 46% YoY plunge, positive insolvency resolutions in India, and minor regulatory fines. Period-over-period trends show revenue growth averaging +20% YoY in high-performers (e.g., Oracle +22%, ICL operating income +47%) but sharp declines in others (-4-46% YoY), with net losses widening in 6/10 detailed reports due to impairments/expenses; capital allocation favors dividends (ICL 3.1% yield, Smurfit +5%) over buybacks. Critical developments like SPAC approvals (TLGY 97% vote) and deal accretions signal bullish consolidation, while Nasdaq delisting risks (GameSquare) and guidance-absent distress (Fenoplast 95% dilution) pose threats. Portfolio-level patterns highlight SPAC resilience amid redemptions (avg 6-100%), Indian regulatory resolutions boosting stability, and tech/hardware growth vs. software weakness, implying opportunities in M&A plays and risks in high-debt growers like Oracle ($134B debt).

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 11, 2026

Overnight SEC filings reveal mixed financial performances across sectors, with standout revenue growth in tech/AI (Oracle +22% YoY to $17.2B, TSS +66% YoY to $245.7M, AeroVironment +143% YoY to $408M Q3) offset by sharp declines (C3.ai -46% YoY to $53.3M, Target Hospitality -17% YoY to $320.6M) and margin compressions (Smith Douglas gross margin -440 bps to 21.8%). SPAC activity dominates with merger approvals (TLGY 97% quorum, near-100% approval for StablecoinX), terminations (Yotta), and IPO filings (Pono Capital $150M, BEST SPAC II $100M), signaling ongoing consolidation. M&A momentum builds via Cintas' $5.5B UniFirst acquisition (8x EBITDA, EPS accretive) and Contango ORE's Dolly Varden deal (proxy support from ISS). Capital returns strengthen (ICL $232M dividends +3.1% yield, News Corp $1B buyback, Pangaea $0.05/share dividend + $1M repurchases), while guidance varies (TSS $20-22M EBITDA 2026, Serve Robotics $26M revenue 2026). Portfolio trends show 12/20 quarterly reporters with YoY revenue growth averaging +45% but net losses in 8/20 due to impairments/expenses; watch Nasdaq compliance (GameSquare extension to Sep 2026) and clinical catalysts.

28 high priority 22 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 10, 2026

Across 50 SEC filings from March 10, 2026, overarching themes include widespread C-suite transitions (12+ neutral departures/appointments in healthcare, tech, energy), a financing surge with $5B+ in debt/equity raises (e.g., Applied Digital $2.15B notes, AN2 $40M PP), 15+ debt refinancings/expansions enhancing liquidity, one high-profile bankruptcy confirmation, and asset sales/debt paydowns reducing leverage. Period-over-period trends reveal robust revenue growth in consumer staples (Westrock +39.8% FY2025 YoY sales, Nature’s Sunshine +5.7% FY2025) but mixed EBITDA (Walker & Dunlop -4% YoY to $316M, Westrock Q4 +2.3% gross profit) and frequent margin compression from scale-up costs/investments. Forward-looking signals are optimistic with Westrock 2026 Adj EBITDA guidance $90-100M (+29-44% YoY), Nature’s $500-515M sales (+4-7%), and Walker’s '30 targets ($80B+ originations). No insider trading patterns noted, but capital allocation favors debt reduction (Ashford $95M sale pays $94.7M mortgage) over dividends/buybacks. Portfolio-level: Biotech/energy lead positive catalysts via PP/deals; executive churn signals potential volatility; relative outperformance in refinancings vs deteriorating ops in isolated cases like Nine Energy bankruptcy.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 10, 2026

Across 50 SEC filings for March 10, 2026, dominant themes include widespread equity dilution from ATM offerings, private placements, and shelf registrations (e.g., Trio Petroleum $17.4M sold/18.1M shares, Aclaris $39.8M/12.7M shares, AN2 $40M), signaling capital needs amid mixed FY25 results with average revenue growth of ~10% YoY in reporting companies (TWFG +22%, Arq +10%, Custom Truck +7.9%) but frequent net loss widening (Bullish -$785M vs +$80M, Arq -$52.6M vs -$5.1M, Trailblazer -$8.3M vs +$0.28M) driven by impairments and fair value hits. Healthcare firms reaffirmed FY26 guidance despite regulatory headwinds (Elevance $25.50+ EPS amid CMS sanctions effective March 31, Centene >$3.00 adj EPS), while SPAC/de-SPAC activity surged with amendments facilitating deals (IQM/RAAQ $1.8B value, Horizon Quantum PIPE $111.9M). Energy/mining showed operational challenges (URANIUM sales -59% YoY, Arq pausing GAC production) offset by balance sheet strengthening via raises, and REITs/RE faced revenue declines (Creative Media -6.3%, ACRES NII -19%). Capital allocation leaned toward buybacks (News Corp $1B program) and debt raises (Duke $1.3B notes), with M&A catalysts imminent (Alexander & Baldwin merger ~March 12). Portfolio-level trends highlight margin compression averaging -150bps in 6/10 industrials/energy (Arq -830bps gross), but improving EBITDA in select names (UNFI +23.4%, TWFG +47%). Implications favor monitoring biotech catalysts and SPAC closes for alpha, while dilution risks weigh on small caps.

23 high priority 27 medium 50 total filings
· daily

Global High-Priority Regulatory Events — March 10, 2026

Across 50 filings centered on global high-priority events like insolvencies, SPACs, IPOs, and M&A, a dominant theme is financial distress in Indian infrastructure firms (e.g., Morarjee Textiles, VAS Infrastructure, Setubandhan) with ongoing CIRP and NCLT hearings signaling prolonged uncertainty. Biotech and SPAC sectors show mixed results: revenues grew in select cases like TWFG (+22% YoY) and Custom Truck (+7.9% YoY), but net losses widened sharply in biotechs (e.g., Cullinan +31% YoY, Rapport +42% YoY) due to R&D surges amid clinical investments. Period-over-period trends reveal revenue growth averaging +10-20% in resilient sectors like insurance (TWFG) and rentals (Custom Truck), contrasted by asset impairments and sales declines in energy/mining (Arq net loss to $52.6M, Uranium sales -59% YoY). Positive catalysts include SPAC mergers (IQM/RAAQ at $1.8B valuation, Horizon Quantum PIPE amendments) and strategic deals (Atlas Energy $840M Caterpillar pact), while insolvencies cluster around March 20 NCLT decisions. Capital allocation leans toward dilutions (e.g., Guided Therapeutics +5.6%) and cash raises over buybacks/dividends, with no major insider buys but executive changes (e.g., Playtika CFO resignation). Overall, portfolio-level patterns favor monitoring turnaround plays in SPACs/energy amid broad margin pressures (e.g., ACRES yield -150bps YoY). Actionable now: Avoid Indian insolvency names; eye SPAC closes and biotech cash runways.

50 high priority 50 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 10, 2026

Overnight SEC filings reveal a diverse mix of 50 reports dominated by biotech and energy sector financings (e.g., Aclaris $39.8M, AN2 $40M), SPAC/M&A advancements (e.g., Alexander & Baldwin merger approved, IQM-RAAQ), and healthcare guidance reaffirmations amid risks (Elevance, Centene). Period-over-period trends show revenue growth in select areas like TWFG (+22% YoY), Custom Truck (+7.9% YoY), Arq (+10% YoY), but widespread margin compression (Arq gross margin -830 bps YoY, ACRES yield -155 bps), impairments (Arq $45M, Trailblazer assets -84% YoY), and losses widening (Bullish $785M net loss, BioNTech operating loss deepened). Capital allocation leans toward dilutions via ATMs/private placements (Trio $17.4M sold, 10+ shelf/S-1/F-1 filings) and buybacks (News Corp $1B program), with insider/activist activity limited but notable (Lululemon 13D/A nominations). Forward-looking catalysts cluster in Q2 2026 (Pershing Vantage close, Lipocine topline April), signaling portfolio-level caution on dilution-heavy small-caps versus stability in large-cap healthcare/insurance. Sector themes highlight biotech resilience via milestones despite cash burns, SPAC amendments easing paths to close, and industrial turnarounds via guidance (Arq FY26 $120-125M rev). Actionable now: Favor guidance-steady names, monitor merger votes.

24 high priority 26 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 09, 2026

Across 50 US SEC filings from March 9, 2026, dominant themes include a surge in M&A activity (e.g., Aureus Greenway merger, Lisata acquisition, CACI's $2.6B ARKA buy), biotech clinical and financing momentum (Relmada's 76% CR rate, Korro's $85M PIPE), and extensive leadership transitions (18+ appointments/resignations). Period-over-period trends show biotech cost efficiencies with 4/6 reporting R&D/OpEx cuts of 19-40% YoY (e.g., Boundless Bio -26% R&D Q4, Spruce -40% OpEx FY2025) amid narrowing net losses (-11% to -26% YoY), contrasted by energy firms raising capital amid production upticks (Battalion +1,200 bpd Jan vs Dec). Capital allocation leans toward equity/debt raises ($500M+ aggregate PIPEs/securitizations) and buybacks (Ingram Micro $50M), with positive sentiment in 60% of high-materiality filings (>8/10). Portfolio implications: Biotech overweight for catalysts like Phase 3 trials mid-2026; monitor energy leadership voids (Gulfport CEO exit). Forward catalysts cluster in Q2 2026 (merger closings, tender offers). Overall, actionable bullish tilt in growth sectors despite mixed leadership signals.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — March 09, 2026

Across 50 SEC filings for March 9, 2026, dominant themes include robust product revenue growth in biotech/pharma (e.g., ARS Pharma +888% YoY product rev to $72.2M) offset by surging expenses and widened losses (avg net loss expansion in 7/12 healthcare firms), SPAC extensions/mergers signaling prolonged deal hunts, and divergent energy results with dredge/oil producers outperforming producers (GLDD rev +16.5% YoY vs W&T -4.5%). Period-over-period trends show 14/25 10-Ks with revenue growth averaging +85% YoY in high-flyers like SharpLink (+666%) and BETA (+136%), but margin compression in 9/15 mixed sentiment firms (e.g., Cross Country operating loss to $84M from $17M) and SPAC cash burns. M&A activity surges with 5 deals (Aureus, Mission Produce, Xanadu), capital raises total >$100M (Bunker Hill C$33.7M, Battalion $15M), and positive guidance in Korn Ferry (Q4 rev $730-750M). Portfolio-level patterns flag healthcare turnaround potential amid commercialization ramps, energy FCF resilience despite price weakness, and SPAC dilution risks. Critical implications: Investors should prioritize firms with narrowing losses (Cumberland -55% YoY) and upcoming catalysts like closings/approvals, while monitoring SPAC liquidations.

31 high priority 19 medium 50 total filings